196 Results for "

Isoform selectivity

" in MedChemExpress (MCE) Product Catalog:
Products (196)

196 Results for "Isoform selectivity" in MCE Product Catalog:

48
48 Publications Verification
Cat. No.: HY-13001
CAS No.: 950769-58-1
Purity:  99.08%
Synonyms: AC220
Target:  

FLT3 Apoptosis PDGFR c-Kit

Research Areas:  

Cancer

Quizartinib (AC220) is an orally active, potent and selective FLT3 inhibitor. Quizartinib inhibits kinase activity of mutant-FLT3, -PDGFRA and -KIT isoforms and inhibits autophosphorylation. Quizartinib inhibits cellular proliferation, induces apoptosis in cancer cells. Quizartinib can be used for the research of cancer .
loading...
    loading...
48
48 Publications Verification
Cat. No.: HY-14217
CAS No.: 1132827-21-4
Purity:  99.81%
Synonyms: AC220 dihydrochloride
Target:  

FLT3 Apoptosis PDGFR c-Kit

Research Areas:  

Cancer

Quizartinib (AC220) dihydrochloride is an orally active, potent and selective FLT3 inhibitor. Quizartinib dihydrochloride inhibits kinase activity of mutant-FLT3, -PDGFRA and -KIT isoforms and inhibits autophosphorylation. Quizartinib dihydrochloride inhibits cellular proliferation, induces apoptosis in cancer cells. Quizartinib dihydrochloride can be used for the research of cancer .
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-12481
CAS No.: 1523406-39-4
Purity:  99.74%
Target:  

PI3K Autophagy

Research Areas:  

Cancer

SAR405 is a first-in-class, selective, and ATP-competitive PI3K class III (PIK3C3) isoform Vps34 inhibitor (IC50=1.2 nM; Kd=1.5 nM). SAR405 inhibits autophagy induced either by starvation or by mTOR inhibition. Anticancer activity .
loading...
    loading...
36
36 Cited Publications
Cat. No.: HY-17356
CAS No.: 49562-28-9
Research Areas:  

Cardiovascular Disease Cancer

Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
loading...
    loading...
31
31 Cited Publications
Cat. No.: HY-15224
CAS No.: 950762-95-5
Purity:  99.84%
Target:  

HDAC Apoptosis

Research Areas:  

Cancer

PCI-34051 is a potent and selective HDAC8 inhibitor with IC50 of 10 nM, with >200-fold selectivity over the other HDAC isoforms.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-13223
CAS No.: 670220-88-9
Purity:  99.67%
Synonyms: CP-868596
Target:  

FLT3 PDGFR Autophagy

Research Areas:  

Cancer

Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-13223A
CAS No.: 670220-93-6
Synonyms: CP 868596-26
Target:  

Autophagy PDGFR FLT3

Research Areas:  

Cancer

Crenolanib benzenesulfonate is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-12866
CAS No.: 1223403-58-4
Purity:  99.95%
Synonyms: LOXO-101; ARRY-470
Target:  

Trk Receptor Apoptosis

Research Areas:  

Cancer

Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-12866A
CAS No.: 1223405-08-0
Purity:  98.96%
Synonyms: LOXO-101 sulfate; ARRY-470 sulfate
Target:  

Trk Receptor Apoptosis

Research Areas:  

Cancer

Larotrectinib sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-100022
CAS No.: 1849590-01-7
Purity:  99.92%
Synonyms: eFT508
Target:  

MNK PD-1/PD-L1

Research Areas:  

Cancer

Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines . Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-117661
CAS No.: 1818389-84-2
Target:  

SRPK VEGFR

Research Areas:  

Cardiovascular Disease Cancer

SPHINX31 is a potent and selective SRPK1 inhibitor, with an IC50 of 5.9 nM. SPHINX31 inhibits phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1). SPHINX31 also decreases the mRNA expression of pro-angiogenic VEGF-A165a isoform. SPHINX31 can be used to research neovascular eye disease .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-15245
CAS No.: 1372540-25-4
Purity:  99.59%
Target:  

PI3K

Research Areas:  

Cancer

GSK2636771 is a potent, selective and orally bioavailable inhibitor of PI3Kβ with a Ki of 0.89 nM and an IC50 of 5.2 nM, showing 900-fold selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms.
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-13802
CAS No.: 354812-17-2
Purity:  99.89%
Synonyms: GK 01140
Target:  

IKK

Research Areas:  

Cancer

SC-514 is a selective IKK-2 inhibitor (IC50=11.2 μM), which does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-11010
CAS No.: 345987-15-7
Purity:  98.19%
Target:  

JNK

AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. AS601245 exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. Neuroprotective properties .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-12513
CAS No.: 1386874-06-1
Purity:  99.27%
Synonyms: LY3023414
Target:  

PI3K DNA-PK mTOR Autophagy

Research Areas:  

Cancer

Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. Samotolisib potently inhibits mTORC1/2 at low nanomolar concentrations .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-126073
CAS No.: 672286-03-2
Purity:  99.46%
Target:  

Aquaporin

Research Areas:  

Inflammation/Immunology Cancer

DFP00173 is a potent and selective aquaporin-3 (AQP3) inhibitor. DFP00173 inhibits mouse and human AQP3 with an IC50 of ~0.1-0.4 μM. DFP00173 is selective for AQP3 over the homologous AQP isoforms AQP7 and AQP9 .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-17464
CAS No.: 73963-72-1
Synonyms: OPC 13013
Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-119254
CAS No.: 2099142-76-2
Purity:  98.33%
Research Areas:  

Metabolic Disease

BAY-850, a chemical probe, is a potent and isoform selective ATPase family AAA domain-containing protein 2 (ATAD2) inhibitor, with an IC50 of 166 nM .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-139004
CAS No.: 2470424-39-4
Purity:  99.67%
Target:  

Casein Kinase

Research Areas:  

Neurological Disease

SGC-CK2-1 is a highly potent, ATP-competitive, and cell-active CK2 chemical probe with exclusive selectivity for both human CK2 isoforms, with IC50s of 36 and 16 nM for CK2α and CK2α′respectively in the nanoBRET assay. SGC-CK2-1 can be used for the research of neurodegenerative diseases .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-126585
CAS No.: 3031-95-6
Purity:  99.57%
SAICAR is an intermediate of de novo purine nucleotide biosynthesis, activates pyruvate kinase isoform M2 (PKM2) in an isozyme-selective manner, with an EC50 of 0.3 mM. SAICAR stimulates PKM2 and promotes cancer cell survival in glucose-limited conditions .
loading...
    loading...